InvestorsHub Logo
Followers 20
Posts 1059
Boards Moderated 0
Alias Born 04/01/2013

Re: yoyo88 post# 10906

Friday, 07/19/2013 4:17:39 PM

Friday, July 19, 2013 4:17:39 PM

Post# of 426290
What you say is what I expect also, though maybe right after Adcom and before December approval.

I am a little concerned about the recent wording mentioning "if GIA for Anchor", really waiting on next CC to take a bigger position or not. Need to see what JZ says about Anchor. I believe partnership is #1 to them but want to get some reassurance.

Partnership on favorable terms for Anchor is paramount for stock price. They may need to take less than they want and less control than they want but they need to do it as WS wants it.

VVUS basically had a large shareholder take over the board and appoint a CEO because VVUS did not partner for their drug. JZ beware!

ARNA partnered and not doing a whole lot better to start than VVUS though slightly better. So its not a be all end all but AMRN is attacking PCP's with a large market and GSK trying to cut them down at every turn since GSK has so much off label useage.

The right partner and Vascepa could do 1 billion in year 1, no partner and we could see 200 million in year 1.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News